Page 25 of 26
PA31.1-10 | Endocrine System — Case Study
CLINICAL SCENARIO
This assignment presents a real-world clinico-pathological scenario involving a thyroid nodule, its cytological evaluation by fine-needle aspiration cytology (FNAC), and subsequent histopathological diagnosis of papillary thyroid carcinoma. You will work through the clinical presentation, interpret cytological and histological findings, reconstruct the pathogenesis and molecular basis of the tumour, and apply prognostic staging.
The goal is not recall but pathological reasoning: you are expected to explain why the morphological features look the way they do, how the tumour spreads, and what determines a patient's prognosis. Peers will review each other's submissions using the structured rubric below.
Instructions
Read the clinical vignette carefully before writing. Your response should be 600–900 words, written in continuous prose organised under the five headings provided in the Scaffolding section. Do not use bullet points for your main analysis; reserve them only for differential diagnoses where listed. Each section carries specific marks; address all prompts within it. Upload your completed assignment as a single PDF or Word document. After submission you will be assigned two peers whose work you will review using the peer review form within 72 hours.
Clinical Vignette:
Mrs. Kamala Devi, a 38-year-old schoolteacher, presents to the outpatient department with a painless swelling on the right side of the neck that she first noticed eight months ago. It has gradually enlarged. She reports no dysphagia, dysphonia, or symptoms of thyroid dysfunction. On examination, a 2.5 × 2.0 cm firm, non-tender nodule is palpable in the right lobe of the thyroid; it moves on swallowing. There is a single 1.2 cm firm lymph node palpable in the right level-III cervical chain. Serum TSH is 1.8 mIU/L (normal 0.4–4.0). Ultrasound shows a hypoechoic nodule with irregular margins, punctate echogenic foci, and no peripheral halo. FNAC is performed; the cytology report reads: 'cellular smears showing papillary fronds lined by follicular cells with enlarged, oval, grooved nuclei; nuclear inclusions and powdery chromatin noted; colloid scant; diagnosis: papillary carcinoma of the thyroid (Bethesda Category VI).' The patient undergoes total thyroidectomy with right central-compartment lymph-node dissection. Histopathology confirms papillary thyroid carcinoma (classical variant), pT2 N1a M0 (AJCC 8th edition), with extrathyroidal extension confined to perithyroidal soft tissue.
Length: 600–900 words (excluding headings and references). Aim for analytical depth over breadth; quality of pathological reasoning carries more weight than completeness of recall.
What to Submit
Clinical Summary and Differential Diagnosis
Briefly summarise the salient clinical and radiological features of this case. Before the FNAC result was available, list the top three differential diagnoses for a solitary thyroid nodule with these ultrasound characteristics (provide one short justification for each). Identify which radiological features in this case raised the suspicion of malignancy rather than a benign nodule, and explain the pathological basis for each suspicious feature.
Interpretation of FNAC Findings
Explain each of the cytological features mentioned in the FNAC report — papillary fronds, nuclear grooves, intranuclear pseudoinclusions, and powdery ('Orphan Annie eye') chromatin — in terms of the underlying structural or nuclear changes that produce them. Why is colloid scant in papillary carcinoma? Describe the Bethesda System for Reporting Thyroid Cytopathology (BSRTC) and explain the clinical significance of a Category VI diagnosis for patient management.
Pathogenesis and Molecular Basis
Reconstruct the pathogenetic sequence that leads to papillary thyroid carcinoma. Your answer should address: (a) the principal oncogenic drivers (BRAF V600E, RET/PTC rearrangements) and the signalling pathway they dysregulate; (b) the role of the thyroid follicular cell as the cell of origin and how it retains differentiation markers (thyroglobulin, TTF-1) even after malignant transformation; (c) any known environmental or genetic risk factors relevant to this patient's age and tumour type.
Histopathology, Spread, and Staging
Describe the classical histopathological features of papillary thyroid carcinoma that would be present on the resection specimen (architecture and nuclear features). Explain why papillary carcinoma spreads preferentially via the lymphatic route rather than the haematogenous route, and describe the typical nodal drainage pattern from the thyroid. Using the information provided, justify the pT2 N1a M0 staging. Explain what 'extrathyroidal extension confined to perithyroidal soft tissue' means prognostically under the AJCC 8th edition — is it a significant adverse feature in this patient?
Prognosis and Post-Operative Management
Papillary thyroid carcinoma has an excellent prognosis; explain the biological reasons for this. Describe the role of radioactive iodine (RAI) ablation and the basis on which it is or is not recommended for this patient (reference the ATA risk stratification). What serum marker would be used to monitor for recurrence and why is it appropriate? Briefly describe two scenarios in which a patient with papillary carcinoma could have a worse prognosis, linking each to a specific pathological or molecular feature.
Integrated Pathological Reasoning — Synthesis
In a single cohesive paragraph (100–150 words), integrate your findings across all sections: connect the ultrasound features → FNAC findings → histopathological diagnosis → molecular driver → clinical behaviour → prognosis in a logical chain. Demonstrate that you understand how each step follows from the preceding one, rather than treating them as isolated facts.
Grading Rubric — Endocrine Case Study Rubric — Papillary Thyroid Carcinoma (30 Points)
| Criterion | Points | Full-marks descriptor |
|---|---|---|
| Clinical Interpretation and Differential Diagnosis — assesses the student's ability to extract relevant clinical and radiological clues, construct a reasoned differential, and link each suspicious ultrasound feature to its underlying pathological basis. | 5 pts | Identifies all three relevant differentials with accurate, concise justifications. Correctly explains the pathological basis of ≥3 suspicious ultrasound features (e.g., punctate echogenic foci as psammoma bodies, hypoechoic texture reflecting dense cellularity, absence of halo indicating infiltrative margin). Reasoning is precise and uses correct terminology. |
| Cytological Interpretation — assesses the student's understanding of the nuclear and architectural features on FNAC and their structural basis, plus knowledge of the Bethesda classification and its clinical relevance. | 6 pts | Accurately explains the structural basis of all four nuclear features (grooves, pseudoinclusions, powdery chromatin, papillary fronds) and correctly attributes scant colloid to loss of follicular architecture. Precisely describes the Bethesda system and explains the management algorithm for Category VI with appropriate nuance (e.g., immediate surgery without repeat cytology). |
| Pathogenesis and Molecular Basis — assesses understanding of the oncogenic drivers, the dysregulated signalling cascade, the paradox of retained differentiation, and relevant risk factors. | 7 pts | Correctly identifies BRAF V600E and RET/PTC as the principal drivers and accurately traces MAPK/ERK pathway dysregulation through to uncontrolled proliferation and impaired apoptosis. Explains retention of thyroglobulin and TTF-1 expression as evidence of differentiation and explains its clinical utility (RAI uptake, tumour marker). Identifies at least two relevant risk factors (e.g., prior ionising radiation, female sex, young age) with mechanistic context. |
| Histopathology, Lymphatic Spread, and Staging — assesses the ability to describe macroscopic and microscopic features, explain the biological basis of lymphatic tropism, and correctly apply TNM staging. | 6 pts | Accurately describes classical histopathological features (papillary architecture, fibrovascular cores, ground-glass 'Orphan Annie eye' nuclei, nuclear grooves/inclusions, psammoma bodies). Correctly explains lymphatic preference via tumour cell production of VEGF-C and lymphangiogenesis, and describes the standard central-compartment (level VI) drainage pathway. Justifies pT2 N1a M0 staging correctly with reference to AJCC 8th edition criteria and correctly interprets the limited extrathyroidal extension as not upstaging in patients under 55. |
| Prognosis, Surveillance, and Post-operative Management — assesses understanding of why the tumour carries a favourable prognosis, the RAI decision framework, the role of thyroglobulin monitoring, and the recognition of adverse prognostic features. | 4 pts | Explains excellent prognosis through biological attributes: retained sodium-iodide symporter (NIS) enabling RAI, slow growth, apoptosis sensitivity, low rate of dedifferentiation. Correctly applies ATA risk stratification to this patient (intermediate risk, N1a, ETE) and recommends adjuvant RAI with justification. Identifies thyroglobulin as the surveillance marker and explains its appropriateness (tumour-specific, synthesised only by thyroid/thyroid cancer cells). Describes two valid adverse-prognosis scenarios (e.g., tall-cell variant, BRAF + TERT co-mutation, distant metastases, anaplastic transformation) with pathological linkage. |
| Integrated Synthesis Paragraph — assesses whether the student can construct a coherent logical chain connecting imaging → cytology → histopathology → molecular pathogenesis → clinical behaviour → prognosis, demonstrating integrative pathological thinking rather than compartmentalised recall. | 2 pts | Synthesis paragraph is coherent, concise (within word limit), and correctly links each step to the next with explicit causal or mechanistic language (e.g., 'because', 'as a result of', 'which explains why'). All six conceptual nodes are connected and the paragraph reads as integrated reasoning, not a summary list. |
PEER REVIEW
You will review two of your peers' submissions within 72 hours of the submission deadline. Use the rubric above as your guide. For each criterion, award the appropriate point level and write 2–3 sentences justifying your score — cite specific content from their submission (e.g., 'You correctly explained that nuclear grooves arise from nuclear membrane redundancy, which is accurate, but you did not connect this to the cytoskeletal changes in papillary carcinoma'). Do not award marks based on length; base every score on the quality of pathological reasoning. Identify one strength and one area for improvement in your overall comments. Your peer review must be constructive, specific, and based on medical accuracy — vague praise ('well written') or vague criticism ('needs more detail') will not be accepted. Faculty reserve the right to moderate grades where peer review scores diverge by more than 4 points from the faculty-assigned mark.